Dishman Carbogen Amcis Ltd Q3 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/bo0ynpmolq09t0tkupzeuv2d.pdf

Key Takeaways


French Facility: From Overhang to Contributor

Pascal Villemagne: "we finalized GMP production on that site which was validated, released and delivered to the customers."

Carbogen Amcis CRAMS: Pipeline at a Record High

Pascal Villemagne: "I would like to, I would love to, because that would make our life much more simpler, but it's almost impossible to predict a number."

India CRAMS: Regulatory Reset Complete

Sanjay Majumdar: "the cost base has increased because of the increased compliances that we have put in place both at the Bavla site and the Naroda site. So, yes, the cost base has increased from what it was three-and-a-half, four years back."

Vitamin D Analogues & Cholesterol: Margin Squeeze from Wool Grease


Costs, Margins & the Employee Cost Question

Harshil Dalal: "I mean, what we sell is the talent, is the technical capability that we have at the Swiss entity and that attracts our customers the most. What we are trying to do is to try and see how we could reprice the project as far as the development work is concerned. But it would be very difficult for us to reduce that cost from what the cost is currently."

Balance Sheet & Capital Allocation


Guidance & Commitments

CommitmentSpecificsTimeline
Consolidated revenue growth"Higher mid to higher teens" top-line growthFY25
Consolidated EBITDA growth"Very considerably strong EBITDA growth" with normalization in almost all quartersFY25
Consolidated EBITDA marginInternally targeted at ~20% (transition year); move to 24–25% thereafterFY25 / medium term
French facility revenue€7–8 mn in Q4; ~€20 mn budgeted for FY25Q4 FY24 / FY25
French facility profitabilityBreakeven at ~€17–18 mn; "a little bit in profit" at ~€20 mnFY25
India CRAMS growth"At least high double digits"; closer to pre-EDQM levelsFY25
India CRAMS revenue~₹300–350 crore called "a fair assessment" by managementFY25
Wool grease pricesExpected to normalizeNext quarter
ADC molecule revenuesProduction and revenues from Swiss ADC expansion to startFY25
Interest costDecline from ₹115 crore to ~₹60–65 crore3–4 years
Net debt (Swiss Franc)Reduce to ~₹10–11 crore of CHF debt3–4 years
3–5 year consolidated CAGRClose to ~15% revenue CAGR; EBITDA growth "much higher than 12–15%"3–5 years
ROCEMove toward 20–25% medium term, 30% long termMedium / long term

Key Metrics

MetricQ3 FY24
Consolidated revenue₹651 cr, +2% YoY
Consolidated revenue (9M FY24)₹1,961 cr, +9.3% YoY
EBITDA (excl. notional FOREX)₹119 cr, vs ₹115 cr in Q3 FY23
EBITDA (excl. notional FOREX, 9M FY24)₹309 cr, vs ₹287 cr in 9M FY23
Notional FOREX loss₹76 cr, driven by USD/CHF movement from 0.9156 to 0.8417
Carbogen Amcis CRAMS revenue₹506 cr, +9.4% YoY
Carbogen Amcis CRAMS EBITDA margin (excl. notional FOREX)~20%, vs 22.3% in Q3 FY23 which had exceptionally high Phase 3 supply
Vitamin D analogues and cholesterol revenue₹61 cr, vs ₹82.5 cr in Q3 FY23; decline due to lower cholesterol sales and higher wool grease prices
India CRAMS revenue₹55.6 cr, +21% YoY
India CRAMS EBITDA margin~11%
India Quats and Generics EBITDA margin~7.5%
Net debt₹1,558 cr (INR), 15.8 cr Swiss Franc
Gross debt₹2,105 cr
Interest cost₹33 cr, stated as the peak quarterly run-rate
Capital expenditure (9M FY24)₹2.5 cr, expected ~₹3 cr by FY24 end
French facility Q3 revenue€0.23 cr, with EBITDA loss of €0.14 cr
French facility Q4 FY24 revenue target€7–8 million
French facility FY25 revenue budget~€20 million, with breakeven at ~€17–18 million
Carbogen Amcis CRAMS development pipeline15 cr (total orders in hand), a historical high and 50% increase over two years
Consolidated revenue CAGR target (3–5 year view)~15%
FY25 consolidated EBITDA margin target~20%
India CRAMS revenue target for FY25₹300–350 cr (per an analyst's math, management confirmed as fair)
Employee cost increase due to FX (Q3 FY24 vs Q3 FY23)~₹24 cr
Swiss entity employee cost as percentage of Swiss P&L50–55%
Raw material cost as percentage of consolidated revenue~20%
Swiss revenue from developmental work~50%